High-dose cyclophosphamide followed by cisplatinum in the treatment of ovarian cancer
Authors:
- 1 August 1987
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 20 (1) , 48-52
Abstract
Twenty patients with previously untreated ovarian cancer received intensive chemotherapy after initial surgery. Treatment comprised two courses of cyclophosphamide at 7 g/m2 with mesna, re-evaluation with second-look laparotomy where appropriate, followed by five courses of cisplatin at 100 mg/m2. Three patients achieved pathologically documented complete remission (PDCR) with high-dose cyclophosphamide, and eight patients achieved partial remission. Fifteen patients went on to receive cisplatin. Nine of these patients had no assessable disease; of six patients who were assessed for response two achieved PDCR and three achieved partial remission. The overall response rate to the sequential regimen was 14/20 (70%). High-dose cyclophosphamide was associated with marked haematological toxicity, which was cumulative and fatal in two patients. The median duration of first remission was 14 months, and the median duration of survival was 20 months. It is concluded that sequential treatment with high-dose cyclophosphamide and cisplatin appears to be no more effective than conventional treatment in advanced ovarian cancer, judging by the PDCR rate and median survival achieved.Keywords
This publication has 13 references indexed in Scilit:
- Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.Journal of Clinical Oncology, 1985
- A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinomaEuropean Journal of Cancer and Clinical Oncology, 1985
- Long-term survival after chemotherapy for advanced epithelial ovarian carcinomaAmerican Journal of Obstetrics and Gynecology, 1984
- Cardiac changes with cyclophosphamideMedical and Pediatric Oncology, 1981
- MATHEMATIC MODEL FOR RELATING THE DRUG SENSITIVITY OF TUMORS TO THEIR SPONTANEOUS MUTATION-RATE1979
- ACCELERATION OF BONE-MARROW RECOVERY BY PRE-TREATMENT WITH CYCLOPHOSPHAMIDE IN PATIENTS RECEIVING HIGH-DOSE MELPHALANThe Lancet, 1978
- Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamideGynecologic Oncology, 1974
- Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma.1974
- Comparison of the Sensitivity of Normal Hematopoietic and Transplanted Lymphoma Colony-Forming Cells to Chemotherapeutic Agents Administered In Vivo2JNCI: Journal of the National Cancer Institute, 1966
- EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIV. FURTHER STUDY OF CERTAIN BASIC CONCEPTS UNDERLYING CHEMOTHERAPY OF LEUKEMIA.1965